Kangpu Biopharmaceuticals Begins Phase IIa Trial of KPG-818 for Systemic Lupus Erythematosus
Shanghai-based Kangpu Biopharmaceuticals, Ltd has announced the first patient dosing in a multicenter, randomized, double-blind,...
Shanghai-based Kangpu Biopharmaceuticals, Ltd has announced the first patient dosing in a multicenter, randomized, double-blind,...
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that the National Medical Products Administration (NMPA)...